What is sinomenine used for medically?

Sinomenine is used primarily as an immunosuppressive and anti-inflammatory agent, with its hydrochloride salt form (Zhengqingnian) approved in China for the treatment of rheumatoid arthritis. It suppresses NF-κB signaling and reduces pro-inflammatory cytokines including TNF-α and IL-6, and preclinical studies also demonstrate antitumor, analgesic, and neuroprotective properties, though these applications have not yet been validated in large-scale human clinical trials.

What plant does sinomenine come from?

Sinomenine is extracted from the roots and stems of Sinomenium acutum (Thunb.) Rehd. et Wils., a climbing vine native to China and Japan known in traditional Chinese medicine as Caulis Sinomenii or Qing Feng Teng. The plant grows in temperate and subtropical forest margins primarily in Hunan, Hubei, Sichuan, and Yunnan provinces, and its alkaloid content is highest in mature root and stem material.

Is sinomenine safe to take as a supplement?

Sinomenine itself exhibits low cytotoxicity in preclinical models (IC₅₀ >100 μM in macrophage cell lines), and its clinical use in China has produced adverse effects including skin rash and gastrointestinal discomfort at therapeutic doses. However, no formal human safety studies, maximum safe dose data, or drug interaction profiles are established in the international peer-reviewed literature, so use outside of supervised clinical or regulatory contexts should be approached with significant caution.

How does sinomenine work for rheumatoid arthritis?

Sinomenine combats rheumatoid arthritis by blocking NF-κB pathway activation in immune cells and synoviocytes, which reduces transcription of inflammatory mediators including TNF-α, IL-6, and iNOS. Additionally, its partial agonism at the μ-opioid receptor contributes to pain relief, and together these mechanisms suppress both the inflammatory tissue damage and the pain symptoms characteristic of rheumatoid arthritis.

What is the difference between sinomenine and its derivatives?

Sinomenine is the natural parent compound isolated from Sinomenium acutum, with an anti-inflammatory IC₅₀ of approximately 70.86 μM for NO inhibition in macrophage models. Synthetic derivatives created by modifying sinomenine's structure with amino acid side chains or nitrogen-containing heterocycles can achieve significantly greater potency—for example, derivative 17 reaches an IC₅₀ of 30.28 μM for NO inhibition, and antitumor derivatives have shown sub-micromolar cytotoxicity (~121.4 nM) against prostate cancer cell lines—though these derivatives may also carry higher cytotoxicity and are not currently available as consumer supplements.

What does clinical research show about sinomenine's effectiveness for rheumatoid arthritis?

Clinical studies demonstrate that sinomenine suppresses multiple inflammatory pathways central to rheumatoid arthritis, including inhibition of IL-6, TNF-α, and iNOS production in immune cells. Research indicates sinomenine achieves immunosuppressive effects comparable to conventional DMARDs (disease-modifying antirheumatic drugs), with evidence supporting its use in Asian clinical practice for RA management. However, most robust evidence comes from Asian populations, and larger randomized controlled trials in Western populations are still needed to establish global clinical standards.

Who should avoid sinomenine supplementation?

Sinomenine should be avoided or used with caution in individuals with severe hepatic or renal impairment, as metabolism and clearance may be compromised. Pregnant and nursing women should avoid sinomenine due to insufficient safety data in these populations. Additionally, individuals taking immunosuppressive medications or those with active infections should consult healthcare providers before use, as sinomenine's immunosuppressive properties may interact with these conditions.

How do synthetic derivatives of sinomenine compare to the natural compound in terms of potency?

Synthetic derivatives of sinomenine, such as derivative 17, demonstrate significantly improved anti-inflammatory potency in laboratory studies, achieving nitric oxide (NO) inhibition at IC₅₀ values of 30.28 μM compared to the parent compound's 70.86 μM in macrophage models. This 2.3-fold improvement in potency suggests that structural modifications can enhance the compound's ability to suppress inflammatory mediators. However, the clinical relevance and bioavailability of these derivatives in humans remain under investigation, and the natural compound remains the standard form in established medical use.

Sinomenine

Sinomenine is a morphinan-class isoquinoline alkaloid that exerts immunosuppressive and anti-inflammatory effects primarily by blocking NF-κB activation, suppressing iNOS, IL-6, and TNF-α expression, and engaging μ-opioid receptor signaling. Preclinical evidence demonstrates that synthetic derivatives achieve NO inhibition with IC₅₀ values as low as 30.28 μM (versus 70.86 μM for sinomenine itself), and in vivo tumor xenograft studies report significant growth reduction at doses of 70–150 mg/kg, though no human clinical trial data with quantified effect sizes have been published.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Sinomenine is the primary bioactive isoquinoline alkaloid isolated from the roots and stems of Sinomenium acutum (Thunb.) Rehd. et Wils., a climbing vine native to temperate and subtropical regions of China and Japan, commonly growing in forest margins and along stream banks at elevations up to 1,500 meters. The plant, known in traditional Chinese medicine as Caulis Sinomenii or Qing Feng Teng, has been cultivated and harvested from wild populations primarily in the provinces of Hunan, Hubei, Sichuan, and Yunnan. Root and stem material is the principal source of commercial sinomenine extraction, with alkaloid content varying by plant maturity, harvest season, and geographic provenance.

Historical & Cultural Context

Sinomenium acutum has been documented in Chinese materia medica for over a millennium, with Caulis Sinomenii (Qing Feng Teng, literally 'green wind vine') appearing in classical TCM texts as a remedy for wind-damp bi-syndrome, a diagnostic category encompassing rheumatic joint pain, swelling, and stiffness analogous to arthritis. The plant's analgesic and anti-inflammatory properties were harnessed through water decoctions and wine-based preparations intended to dispel wind, eliminate dampness, and unblock the channels—TCM concepts corresponding to its modern immunosuppressive and anti-nociceptive mechanisms. Historical use also extended to conditions including neuralgia, edema, and skin disorders, reflecting the broad anti-inflammatory utility now partially validated in preclinical research. In contemporary Chinese medicine, sinomenine hydrochloride represents a successful phytochemical-to-pharmaceutical translation, having achieved regulatory drug status in China while retaining its roots in classical botanical practice.

Health Benefits

- **Anti-Inflammatory Activity**: Sinomenine suppresses lipopolysaccharide-induced inflammatory mediators including iNOS, IL-6, and TNF-α in a dose-dependent manner; synthesized derivative 17 achieves NO inhibition at IC₅₀ = 30.28 ± 1.70 μM in RAW264.7 macrophages, outperforming the parent compound at 70.86 ± 1.00 μM.
- **Immunosuppression in Rheumatoid Arthritis**: Sinomenine has been used clinically in China as an approved immunosuppressive agent for rheumatoid arthritis, modulating T-cell and macrophage activity through NF-κB pathway inhibition and cytokine downregulation, reducing synovial inflammation in preclinical joint models.
- **Antitumor Potential**: Sinomenine and its derivatives exert cytotoxic effects against multiple cancer cell lines including HeLa, MDA-MB-231, Hep3B, U87, PC-3, and DU-145, with some derivatives reaching IC₅₀ values as low as ~121.4 nM in prostate cancer cells by activating caspase-3 and modulating Bax/Bcl-2 ratios.
- **Neuroprotection**: Sinomenine activates Nrf2 antioxidant signaling and modulates MAPK pathways, demonstrating neuroprotective effects in preclinical models of neuroinflammation and oxidative stress-induced neuronal injury, partly mediated through its μ-opioid receptor agonism.
- **Analgesic Effects**: Via μ-opioid receptor engagement, sinomenine produces centrally and peripherally mediated analgesia in rodent pain models, offering a mechanistic basis for its traditional use in rheumatic pain management without the full opioid adverse effect profile.
- **Organ-Protective Properties**: Preclinical studies indicate sinomenine confers protective effects on cardiac, renal, and hepatic tissue under inflammatory or ischemic conditions, engaging both Nrf2-mediated antioxidant defenses and suppression of MAPK-driven inflammatory cascades.
- **Antitumor Cell Cycle Disruption**: Sinomenine downregulates cyclin D1, cyclin E, CDK4, survivin, and MMP-2/9 while upregulating p21 and inducing ER stress and ROS accumulation, collectively arresting tumor cell proliferation and inhibiting metastatic invasion across multiple cancer models.

How It Works

Sinomenine inhibits the NF-κB signaling pathway by preventing IκB phosphorylation and nuclear translocation of the p65 subunit, thereby suppressing transcription of pro-inflammatory genes encoding TNF-α, IL-6, and iNOS in macrophages and synoviocytes. Simultaneously, sinomenine acts as a partial agonist at the μ-opioid receptor, contributing to its analgesic and potentially immunomodulatory effects through cAMP suppression and MAPK modulation. In oncological contexts, sinomenine and its derivatives engage the PI3K/Akt/mTOR and JAK/STAT pathways, increasing Bax/Bcl-2 ratios, activating caspase-3 and caspase-9 cascades, elevating intracellular ROS, and triggering endoplasmic reticulum stress to drive apoptosis and cell cycle arrest at G0/G1 and G2/M checkpoints. Neuroprotective and organ-protective mechanisms additionally involve activation of the Nrf2/ARE antioxidant response element, upregulating heme oxygenase-1 and superoxide dismutase expression to counteract oxidative injury.

Scientific Research

The current evidence base for sinomenine is predominantly preclinical, consisting of in vitro cell-line studies and rodent in vivo xenograft or inflammatory models, with no peer-reviewed human randomized controlled trials reporting quantified effect sizes identified in the available literature. In vitro studies have characterized sinomenine's anti-inflammatory IC₅₀ values in LPS-stimulated RAW264.7 macrophages and antitumor activity across HeLa, MDA-MB-231, Hep3B, PC-3, DU-145, and U87 cell lines, with derivative compounds reaching sub-micromolar potency (~121.4 nM). Animal studies using 70–150 mg/kg sinomenine have demonstrated statistically significant reductions in xenograft tumor volume and increased apoptotic indices, and adjuvant arthritis rodent models show joint inflammation suppression, but translation to human populations remains unvalidated. Sinomenine hydrochloride has regulatory approval as a prescription anti-rheumatic drug in China (under the brand Zhengqingnian), suggesting real-world clinical use, but peer-reviewed English-language RCT data with defined sample sizes, confidence intervals, and standardized outcome measures are lacking in the publicly accessible literature.

Clinical Summary

Sinomenine hydrochloride is approved and prescribed in China for rheumatoid arthritis management, providing a foundation for translational confidence, but the publicly available peer-reviewed clinical trial data are insufficient to define robust effect sizes or comparative efficacy against standard disease-modifying antirheumatic drugs (DMARDs). Preclinical anti-inflammatory outcomes in cell and animal models are consistently positive, with well-characterized molecular targets, but these results cannot be directly extrapolated to human dosing or therapeutic windows without formal phase II/III RCT data. Antitumor effects reported across multiple cancer cell lines and xenograft models are mechanistically compelling but remain in the early preclinical stage, with no clinical oncology trials identified. Overall, clinical confidence is moderate for the anti-rheumatic application in the Chinese regulatory context but must be considered preliminary by international evidence-based medicine standards due to the absence of published large-scale RCTs with standardized reporting.

Nutritional Profile

Sinomenine is a pure isoquinoline alkaloid compound (molecular formula C₁₉H₂₃NO₄, molecular weight 329.39 g/mol) rather than a nutritional ingredient, and therefore does not possess a conventional macronutrient or micronutrient profile. It is structurally classified within the morphinan alkaloid subclass, sharing a tetracyclic skeleton with morphine-related compounds but lacking opioid abuse liability at physiological doses. Key phytochemical characteristics include a tertiary amine nitrogen responsible for μ-opioid receptor interaction, a methoxy group at C-4 and C-6 positions contributing to NF-κB inhibition, and an α,β-unsaturated ketone moiety relevant to electrophilic reactivity and Nrf2 activation. Bioavailability data from human studies are not established; in animal models, oral absorption occurs but first-pass metabolism and blood-brain barrier penetration have been noted as factors influencing bioactive concentrations at target tissues.

Preparation & Dosage

- **Sinomenine Hydrochloride Tablets (China-approved)**: The clinically used form in China is sinomenine hydrochloride (Zhengqingnian), typically administered orally; common reported dosing in the Chinese clinical context ranges from 20–60 mg three times daily, though no internationally validated standard dose exists.
- **Raw Plant Decoction (Traditional)**: Caulis Sinomenii root and stem material is traditionally prepared as a water decoction in TCM formulations, combined with other herbs; typical crude herb doses in decoctions range from 6–15 g dried material per day.
- **Standardized Extracts**: Research-grade sinomenine is standardized to ≥98% purity by HPLC for experimental use; commercial supplement standardization percentages for consumer products are not established in available literature.
- **Experimental In Vitro Concentrations**: Studies employ 0.0625–2 mM in cell culture models; these concentrations are not translatable to supplemental dosing guidance.
- **In Vivo Animal Doses**: Antitumor and anti-inflammatory animal studies use 50–150 mg/kg body weight, a range that has not been validated for human pharmacokinetic equivalence.
- **Timing Notes**: No human pharmacokinetic data specifying optimal timing relative to meals or circadian rhythm are available; traditional decoctions are typically consumed in divided doses with meals.

Synergy & Pairings

In traditional Chinese medicine formulations, Caulis Sinomenii is commonly paired with Tripterygium wilfordii (Thunder God Vine, also containing immunosuppressive alkaloids and diterpenoids), with the combination theorized to produce additive NF-κB and T-cell suppression relevant to rheumatoid arthritis, though this pairing also compounds hepatotoxicity and reproductive toxicity risks. Preclinical research suggests mechanistic complementarity between sinomenine's NF-κB inhibition and curcumin's IKK suppression and Nrf2 activation, potentially allowing dose reduction of each compound while maintaining anti-inflammatory efficacy. Sinomenine's PI3K/Akt/mTOR antagonism in tumor models has been proposed to synergize with conventional chemotherapeutic agents such as cisplatin or doxorubicin by sensitizing cancer cells to apoptosis, though combination studies remain at the in vitro stage.

Safety & Interactions

Sinomenine itself demonstrates low cytotoxicity in preclinical cell models, with IC₅₀ values exceeding 100 μM in RAW264.7 macrophages, suggesting a reasonable therapeutic index relative to its anti-inflammatory active concentrations; however, certain synthetic derivatives exhibit significantly higher cytotoxicity (IC₅₀ as low as 17.88 μM), highlighting that structural modifications substantially alter the safety profile. No formal human adverse event data, maximum tolerated dose studies, or drug interaction profiling are available in the peer-reviewed English-language literature reviewed; the Chinese clinical experience with sinomenine hydrochloride has noted adverse effects including skin rash and gastrointestinal discomfort at therapeutic doses, consistent with its immunomodulatory mechanism. Given its μ-opioid receptor agonist activity and immunosuppressive properties, theoretical interactions exist with opioid analgesics (additive CNS effects), immunosuppressants such as cyclosporine or methotrexate (additive immunosuppression), and anti-inflammatory drugs (pharmacodynamic overlap); formal drug interaction studies are absent. Sinomenine is contraindicated or should be used with extreme caution in pregnancy and lactation due to complete absence of safety data in these populations, and patients with pre-existing immune deficiency or hepatic impairment should exercise particular caution given the compound's metabolic pathway and immunological activity.